Biogen BIIB Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Biogen’s reported figures.
Based on trailing twelve months.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's return on equity?
- Biogen (BIIB) reported return on equity of 8% in Q1 2026.
- How has Biogen's return on equity changed year-over-year?
- Biogen's return on equity decreased by 13.2% year-over-year, from 9.2% to 8%.
- What is the long-term trend for Biogen's return on equity?
- Over 4 years (2021 to 2025), Biogen's return on equity has grown at a -16.4% compound annual growth rate (CAGR), from 72.3% to 35.3%.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.